TrialBJS open2025

Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial.

Takeru Matsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.